MedTrace Logo

A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer

NCT01752686 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 587

Last updated 2012-12-25

No results posted yet for this study

Summary

This study is designed to investigate the efficacy of carboplatin, as a post-operative adjuvant chemotherapy for triple negative breast cancer patients who have pathologic residual cancer after the preoperative chemotherapy.

Conditions

Interventions

DRUG

carboplatin

carboplatin as adjuvant chemotherapy

Sponsors & Collaborators

  • Severance Hospital

    lead OTHER

Principal Investigators

  • Byeong Woo Park, MD, PhD · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2017-03-31
Completion
2018-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752686 on ClinicalTrials.gov